Clearmind Medicine files Israeli patent for depression treatment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ENPH
2. HOOD
3. NXPI
4. BA
5. STX
6. V
7. CSGP
8. UPS
9. KIDS
10. LSTR

Go back to Clearmind Medicine files Israeli patent for depression treatment

Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

November 17, 2025 7:55 AM EST

Vancouver, Canada, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (Clearmind or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of an Israeli patent application for its innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), addressing depression.

The patent application stems from Clearminds collaboration with Neurothera Labs Inc. (TSXV: NTLX) (Neurothera), a subsidiary of SciSparc Ltd. (Nasdaq: SPRC). This therapy targets depression... More